James Porter serves as the Chief Executive Officer of Nuvalent, guiding the precision oncology enterprise's corporate strategy, scientific research, and clinical development pipeline. With extensive professional experience in biotechnology leadership and drug discovery, he has steered the organization through crucial milestones, including advanced clinical trials and its high-profile integration into GSK's global pharmaceutical operations.